Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation (Nasdaq: QDEL) is a global in vitro diagnostics company that regularly issues news on its products, technologies and financial performance. As a manufacturer of diagnostic solutions spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho generates updates that are relevant to clinicians, laboratory professionals and investors who follow developments in medical diagnostics.
News about QuidelOrtho often covers product clearances and launches, such as FDA 510(k) clearance for the VITROS hs Troponin I Assay to aid in the diagnosis of myocardial infarction, or the availability of the QUICKVUE Influenza + SARS Test, a CLIA‑waived rapid immunoassay that differentiates influenza A, influenza B and SARS‑CoV‑2 from a single sample. These announcements provide insight into how the company is expanding its cardiac, respiratory and point‑of‑care testing portfolios.
The company also issues financial and corporate updates, including quarterly earnings releases, guidance discussions and details of financing arrangements disclosed through press releases and related SEC filings. Investors can track how QuidelOrtho describes its revenue mix, cost‑savings initiatives and capital structure, including credit agreements and refinancing activities.
Another recurring theme in QuidelOrtho’s news flow is educational and thought‑leadership content. Through its Science Bytes podcast, the company highlights topics such as diagnostic trends, early detection of diabetes, the role of informatics in clinical decision‑making and the importance of respiratory testing in urgent care. Episodes feature internal experts and external clinicians and are used to explain how diagnostics intersect with patient care and healthcare economics.
In addition, QuidelOrtho reports on its participation in industry conferences, including events focused on transfusion medicine where it showcases immunohematology products like the MTS DAT Card and ORTHO VISION Platform. For users of this news page, following QDEL news offers a way to monitor product pipeline milestones, regulatory developments, financial disclosures and educational initiatives from a single diagnostics-focused source.
Quidel Corporation (NASDAQ: QDEL) reported a 12% decline in total revenue for Q2 2021, falling to $176.6 million compared to $201.8 million in Q2 2020. COVID-19 product sales decreased to $83.4 million, down from $109.0 million, while influenza product sales plummeted to $1.6 million. GAAP EPS was $0.45, significantly lower than $1.55 in the prior year. Despite challenges, core business revenue grew 24% to $91.5 million, driven by strong performance in Cardiometabolic Immunoassays. The Sofia® SARS Antigen test received Emergency Use Authorization for screening, supporting potential growth.
Quidel Corporation (NASDAQ: QDEL) has announced a new agreement with Beckman Coulter that resolves ongoing litigation and transitions the BNP Business to Beckman Coulter. This deal guarantees Quidel cash payments of between $70 million and $75 million annually until 2029. The arrangement also allows Quidel to focus on its core businesses while ensuring a stable cash flow. Notably, Quidel will stop offering its BNP assay, as Beckman Coulter will introduce its branded product, completing the transition by the end of 2021.
Quidel Corporation (NASDAQ: QDEL) has partnered with the State of Delaware to launch a comprehensive COVID-19 testing program aimed at K-12 schools, facilitating their reopening in the fall. Under this initiative, Quidel will manage staffing, sample collection, testing, and reporting results to the Delaware Division of Public Health. The program will begin at five pilot schools for summer sessions, with potential expansion statewide. Governor Carney emphasizes the importance of this program for student safety and in-person learning.
Quidel Corporation (NASDAQ: QDEL) will announce its fiscal second quarter 2021 financial results on August 5, 2021, after market close. CEO Douglas Bryant and CFO Randy Steward will conduct a conference call at 5:00 p.m. ET to discuss the results and answer questions. The company’s recent innovations in rapid diagnostic testing, particularly for COVID-19, underline its role in enhancing healthcare quality. Access to the live call and subsequent replays is available via their website and specific links provided in the release.
Quidel Corporation (NASDAQ: QDEL) has received the CE Mark for its Savanna® multiplex molecular analyzer and Savanna® RVP4 Assay, allowing sales in Europe and other accepting countries. The Savanna system can analyze up to 12 pathogens in under 30 minutes using real-time PCR tests. The initial RVP4 Assay detects multiple respiratory viruses, including SARS-CoV-2 and influenza strains. CEO Douglas Bryant emphasized the importance of this CE Mark for commercialization, with plans to deploy instruments to international customers to support broader U.S. launch efforts.
Quidel Corporation has launched LymeDiseaseAnswers.com, a resource aimed at educating the public about Lyme disease, which affects nearly 480,000 Americans annually. The website offers information on the prevalence, causes, and symptoms of Lyme disease, as well as the latest testing advances. It features FAQs, infographics, and educational videos. Quidel is known for the Sofia 2 Lyme FIA test, delivering results within minutes. The site has already won the Platinum Award at the MarCom Awards, recognizing its excellence in marketing.
Quidel Corporation has launched a public service campaign to raise awareness about Lyme disease among summer camps as they reopen after two years. The campaign includes educational materials and social media outreach aimed at prevention and early detection. Lyme disease affects about 476,000 Americans annually, often leading to serious complications if not treated promptly. Quidel offers the Sofia® 2 Lyme FIA, a rapid, on-site test delivering results in 15 minutes, enhancing early treatment options. This initiative comes as camps open, reflecting a gradual return to normalcy post-pandemic.
Quidel Corporation's Sofia® 2 Lyme FIA test is gaining traction amid a rising number of Lyme disease cases in the U.S., projected to reach up to 476,000 this year. Various institutions report an unexpected spread of Lyme disease, exacerbated by increased outdoor activity post-COVID restrictions and a warm winter boosting tick populations. The Sofia® 2 Lyme FIA delivers results within 15 minutes instead of days, enabling timely treatment and potentially preventing severe complications of untreated Lyme disease. Quidel emphasizes the importance of early testing to improve patient outcomes.
Quidel Corporation (NASDAQ: QDEL) has received an amended Emergency Use Authorization from the FDA for its new Sofia Q device, which will initially be sold for use with Sofia SARS Antigen FIA tests. This innovative device features a compact design and integrates with a mobile app for easier workflow management and result interpretation. Quidel aims to democratize access to rapid diagnostic testing across various sectors. The Sofia Q enhances the existing Sofia product line, known for its accuracy and efficiency in providing rapid results.
Quidel Corporation (NASDAQ: QDEL) will present at the Raymond James Human Health Innovation Conference 2021 virtually on June 21, 2021, at 1:20 p.m. ET. CEO Douglas Bryant and CFO Randy Steward will discuss the company’s business and financial developments in a Q&A format. The presentation will be accessible via live webcast on the company’s Investor Relations webpage, with a replay available for 14 days. Quidel is a leading provider of rapid diagnostic testing solutions, known for innovation in the medical device industry, including COVID-19 testing.